Safety and Efficacy of Pegcetacoplan in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria over 48 Weeks: 307 Open-Label Extension StudyOriginal Research Published on 2024-04-042024-09-05 Journal: Advances in therapy [Category] update2024, [키워드] clinical trial Complement inhibitor eculizumab FACIT-Fatigue hemoglobin Open-label extension paroxysmal nocturnal hemoglobinuria (PNH) pegcetacoplan thrombosis transfusion [DOI] 10.1007/s12325-024-02827-8 PMC 바로가기 [Article Type] Original Research
Safety Profile of Monoclonal Antibodies and Subsequent Drug Developments in the Treatment of Paroxysmal Nocturnal HemoglobinuriaReview Published on 2024-02-242024-09-05 Journal: Medicina [Category] update2024, [키워드] Adverse drug reaction challenges eculizumab investigational new drugs paroxysmal nocturnal hemoglobinuria Ravulizumab [DOI] 10.3390/medicina60030379 PMC 바로가기 [Article Type] Review
Triple-fusion protein (TriFu): A potent, targeted, enzyme-like inhibitor of all three complement activation pathwaysResearch Article Published on 2024-02-232024-09-05 Journal: Brain stimulation [Category] update2024, [키워드] complement Complement receptor 1 compstatin decay accelerating factor eculizumab Factor H fusion protein paroxysmal nocturnal hemoglobinuria [DOI] 10.1016/j.jbc.2024.105784 PMC 바로가기 [Article Type] Research Article
Atypical hemolytic uremic syndrome triggered by mRNA vaccination against SARS-CoV-2: Case reportArticle Published on 2022-09-282022-11-15 Journal: Frontiers in Immunology [Category] SARS, 변종, 진단, [키워드] activation pathway acute kidney Acute kidney injury affecting allergies Anemia Atypical Atypical hemolytic uremic syndrome Bacterial infections bleeding Case report cause caused CD46 CFH complement complementary disease disorder dysregulation eculizumab effective Factor Factors Genetic genetic risk Haplotype hematological immune-mediated diseases Ischemia life-threatening manifested Mild monoclonal antibody mRNA vaccination mRNA vaccine mRNA vaccine against SARS-CoV-2 Mutation occurred organs pathogenic variant Patient plasma Pregnancy Protein rare disease Ravulizumab renal risk risk factor SARS-CoV-2 scleral the disease the patient thrombotic thrombotic microangiopathies treated Treatment triggered uremic uremic syndrome vaccination [DOI] 10.3389/fimmu.2022.1001366 PMC 바로가기
Severe refractory warm autoimmune haemolytic anaemia after the SARS-CoV-2 Pfizer-BioNTech vaccine (BNT162b2 mRNA) managed with emergency splenectomy and complement inhibition with eculizumabArticle Published on 2022-08-312022-11-15 Journal: BMJ case reports [Category] SARS, 진단, [키워드] 48 hour Autoimmune Bilirubin Blood BNT162b2 mRNA Chest complement Complement pathway Corticosteroid described disease eculizumab fatigue first dose haematology (incl blood transfusion) Haemoglobin highlight inhibitor initiated investigation jaundice lactate dehydrogenase life-threatening liver male over Pfizer-BioNTech SARS-CoV-2 standard treatment the patient the SARS-CoV-2 transplantation Urine Vaccine warm was performed [DOI] 10.1136/bcr-2022-250774 PMC 바로가기
Long-Term Outcomes after Vaccine-Induced Thrombotic Thrombocytopenia백신 유도성 혈전성 혈소판 감소증 후 장기 결과Article Published on 2022-08-012022-09-11 Journal: Viruses [Category] SARS, 진단, 치료기술, [키워드] acute phase Adenovirus adenovirus-based affected antibody Anticoagulants anticoagulation appear Arterial thrombosis AZD1222 bleeding cerebral venous sinus thrombosis ChAdOx1 ChAdOx1 nCoV-19 Cohort Cohort studies cohort study Complication coronavirus Corticosteroids COVID-19 D-dimer detectable diagnosed Diagnosis died dimer Direct discharge discharged eculizumab effective elevated enrolled Follow-up hospital hospital discharge Immunoglobulin in some Intravenous immunoglobulin IVIG limit management nCoV neurological nine observation occurred one patient oral anticoagulant outcome Patient patients PF4 Platelet platelet activation positive prothrombotic condition remained respiratory respiratory syndrome coronavirus respiratory syndrome coronavirus 2 Safe SARS-CoV-2 serious complication Seven severe respiratory syndrome single-center Sinus thrombosis survived Symptom symptom onset syndrome the disease thrombocytopenia thromboembolic Thromboembolic event Thromboembolic events thrombosis thrombotic Thrombotic thrombocytopenia Treatment two patients vaccination Vaccine venous venous sinus were given [DOI] 10.3390/v14081702 PMC 바로가기 [Article Type] Article
Complement blockade with eculizumab for treatment of severe Coronavirus Disease 2019 in pregnancy: A case series임신 중 중증 코로나바이러스 질환 2019 치료를 위해 에쿨리주맙으로 봉쇄 보완: 사례 시리즈Clinical Trial Published on 2022-08-012022-09-12 Journal: American journal of reproductive immunology (New Y [Category] COVID19(2023년), SARS, 임상, 진단, [키워드] Administered Adults adverse outcomes All participant bilateral pulmonary infiltrate blockade case sery center complement complement system proteins COVID-19 Day demonstrated dose eculizumab eligible enrolled evaluated event Expanded Access Program hospital discharge Hospital stay indicated individuals inhibitor mechanical ventilation median multicenter nasal Neonatal non-rebreather mask open label outcome Oxygen requirement participant Patient pharmacokinetic Pregnancy pregnant Primary outcome Protein ranged secondary severe COVID-19 still hospitalized survival the median treat Treatment [DOI] 10.1111/aji.13559 PMC 바로가기 [Article Type] Clinical Trial
Generalized myasthenia gravis patients infected with COVID-19 should continue eculizumabCOVID-19에 감염된 전신성 중증 근무력증 환자는 에쿨리주맙을 계속해야 합니다Article Published on 2022-07-012022-09-12 Journal: Neurological Sciences [Category] MERS, 진단, [키워드] complement coronavirus disease COVID-19 eculizumab Generalized humanized monoclonal antibody indicated infected with COVID-19 Infection inhibitor myasthenia gravis outcome Patient [DOI] 10.1007/s10072-022-05922-2 PMC 바로가기 [Article Type] Article
Cold agglutinin disease secondary to severe SARS-CoV-2 treated with eculizumab에쿨리주맙으로 치료한 중증 SARS-CoV-2에 따른 한랭응집소 질환Case Reports Published on 2022-04-292022-09-12 Journal: BMJ case reports [Category] COVID19(2023년), SARS, 진단, [키워드] acute renal failure acute respiratory distress adult intensive care antibody Cold agglutinin disease COVID-19 Critical died Direct antiglobulin test disease Diseases eculizumab explained French haematology (drugs and medicines) immune response immunological disorder Impaired Infectious diseases Inflammation Intensive intensive care life-threatening monoclonal Occurrence Patient persistent positive reported resolved SARS-COV-2 infection severe coronavirus disease Severe COVID-19 Infection severe SARS-CoV-2 specific treatment syndrome the patient therapy titre Transfusion therapy treated [DOI] 10.1136/bcr-2021-242937 PMC 바로가기 [Article Type] Case Reports
Case Report: Severe Rhabdomyolysis and Multiorgan Failure After ChAdOx1 nCoV-19 Vaccination증례 보고서: ChAdOx1 nCoV-19 백신 접종 후 심각한 횡문근 융해증 및 다기관 부전Case Reports Published on 2022-03-172022-09-12 Journal: Frontiers in Immunology [Category] MERS, SARS, 진단, [키워드] accelerated Anakinra assumption biologic Bone marrow Case report ChAdOx1 ChAdOx1 nCoV-19 characterized creatine phosphokinase cytokine Cytokine storm Deterioration dramatic increase drug eculizumab failure first dose had no healthy hypoglycemia immunosuppressive Infection inflammatory markers kidney liver lung multi organ failure nine occur occurred patient death patients with SARS-CoV-2 PCT physician procalcitonin rapid increase reported resulting rhabdomyolysis Risk factors SARS-CoV-2 SARS-CoV2 Shock Skeletal muscle Steroids therapy Treatment vaccination vaccine administration [DOI] 10.3389/fimmu.2022.845496 PMC 바로가기 [Article Type] Case Reports